Publicaciones en colaboración con investigadores/as de University of Bari Aldo Moro (42)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. Development of N-(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase

    Journal of Medicinal Chemistry, Vol. 66, Núm. 1, pp. 235-250

  2. Fluorescence based HTS-compatible ligand binding assays for dopamine D3 receptors in baculovirus preparations and live cells

    Frontiers in Molecular Biosciences, Vol. 10

  3. N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R)

    European Journal of Medicinal Chemistry, Vol. 248

  4. Novel thienocycloalkylpyridazinones as useful scaffolds for acetylcholinesterase inhibition and serotonin 5-HT6 receptor interaction

    Bioorganic and Medicinal Chemistry, Vol. 84

2022

  1. Design and Synthesis of Arylpiperazine Serotonergic/ Dopaminergic Ligands with Neuroprotective Properties

    Molecules, Vol. 27, Núm. 4

  2. Design, Synthesis and 5-HT1A Binding Affinity of N-(3-(4-(2-Methoxyphenyl)piperazin-1-yl)propyl)tricyclo[3.3.1.13,7 ]decan-1-amine and N-(3-(4-(2-Methoxyphenyl) piperazin-1-yl)propyl)-3,5-dimethyl-tricylo[3.3.1.13,7 ]decan-1-amine

    MolBank, Vol. 2022, Núm. 1

  3. Dose-response assessment of cerebral P-glycoprotein inhibition in vivo with [18F]MC225 and PET

    Journal of Controlled Release, Vol. 347, pp. 500-507

  4. New insights into the genetic etiology of Alzheimer's disease and related dementias

    Nature genetics, Vol. 54, Núm. 4, pp. 412-436

  5. Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A1Antagonists

    Journal of Medicinal Chemistry, Vol. 65, Núm. 3, pp. 2091-2106

2021

  1. 3,4-Dihydropyrimidin-2(1H)-ones as Antagonists of the Human A2B Adenosine Receptor: Optimization, Structure-Activity Relationship Studies, and Enantiospecific Recognition

    Journal of medicinal chemistry, Vol. 64, Núm. 1, pp. 458-480

  2. Evaluation of P-glycoprotein function at the blood–brain barrier using [18F]MC225-PET

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, Núm. 12, pp. 4105-4106

  3. Head-to-head comparison of (R)-[11C]verapamil and [18F]MC225 in non-human primates, tracers for measuring P-glycoprotein function

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 48, Núm. 13, pp. 4307-4317

  4. In Vivo Induction of P-Glycoprotein Function can be Measured with [18F]MC225 and PET

    Molecular Pharmaceutics, Vol. 18, Núm. 8, pp. 3073-3085

  5. Knowledge-Based Design of Long-Chain Arylpiperazine Derivatives Targeting Multiple Serotonin Receptors as Potential Candidates for Treatment of Autism Spectrum Disorder

    ACS Chemical Neuroscience, Vol. 12, Núm. 8, pp. 1313-1327

  6. Pharmacokinetic Modeling of (R)-[11C]verapamil to Measure the P-Glycoprotein Function in Nonhuman Primates

    Molecular Pharmaceutics, Vol. 18, Núm. 1, pp. 416-428

  7. Synthesis and Biological Evaluation of Dantrolene-Like Hydrazide and Hydrazone Analogues as Multitarget Agents for Neurodegenerative Diseases

    ChemMedChem, Vol. 16, Núm. 18, pp. 2807-2816

2020

  1. Design and synthesis of fluorescent ligands for the detection of cannabinoid type 2 receptor (CB2R)

    European Journal of Medicinal Chemistry, Vol. 188

  2. PET imaging of ABC transporters at the blood-brain barrier

    PET and SPECT of Neurobiological Systems (Springer International Publishing), pp. 809-850

  3. Pharmacokinetic Modeling of [18F]MC225 for Quantification of the P-Glycoprotein Function at the Blood-Brain Barrier in Non-Human Primates with PET

    Molecular Pharmaceutics, Vol. 17, Núm. 9, pp. 3477-3486